Institute of Science and Techniques of Physical and Sports Activities, Department of Physical Education and Sports, University of Oum El Bouaghi, Oum El Bouaghi, Algeria.
Institute of Physical Education and Sports, Hassiba Ben Bouali University, Chlef, Algeria.
Phys Sportsmed. 2024 Apr;52(2):134-146. doi: 10.1080/00913847.2023.2186691. Epub 2023 Mar 6.
Many types of COVID19 vaccines are administered globally, yet there is not much evidence regarding their side effects among athletes. This study evaluated the selfreported postvaccination side effects of inactivated virus, adenoviral vector, and mRNA COVID19 vaccines among Algerian athletes.
A cross-sectional survey-based study was carried out in Algeria between March 01 and 4 April 2022. The study used a validated questionnaire with twenty-five multiple-choice items covering the participants' anamnestic characteristics, post-vaccination side effects (their onset and duration), post-vaccination medical care, and risk factors.
A total of 273 athletes completed the survey. Overall, (54.6%) of the athletes reported at least one local side effect, while (46.9%) reported at least one systemic side effect. These side effects were more prevalent among the adenoviral vector group compared to the inactivated virus and mRNA groups. The most common local side effect was injection site pain (29.9%), while Fever (30.8%) was the most prevalent systemic side effect. The age group of 31-40 years, allergy, previous infection with COVID-19, and the first dose of vaccines were associated with an increased risk of side effects for all groups of COVID-19 vaccines. Logistic regression analysis further revealed that compared to males, the incidence of reported side effects was significantly higher in females (odd ratio (OR) = 1.16; P = 0.015*) only for the adenoviral vector vaccine group. In addition, a significantly higher percentage of athletes group of high dynamic/moderate static or high dynamic /high static components suffered from post-vaccination side effects compared to the group of athletes with high dynamic/low static components (OR = 14.68 and 14.71; P < 0.001, respectively).
The adenoviral vector vaccines have the highest rate of side effects, followed by the inactivated virus and mRNA COVID-19 vaccines. COVID‑19 vaccines were well-tolerated among Algerian athletes and there were no reports of serious side effects. Nevertheless, further long-term follow-up study with a larger sample size of athletes (from different types and sports categories) is warranted to establish the long-term safety of the COVID-19 vaccine.
全球范围内使用了多种类型的 COVID19 疫苗,但关于运动员接种疫苗后的副作用的证据并不多。本研究评估了阿尔及利亚运动员接种灭活病毒、腺病毒载体和 mRNA COVID19 疫苗后的自我报告的疫苗接种后副作用。
2022 年 3 月 1 日至 4 月 4 日在阿尔及利亚进行了一项基于横断面调查的研究。该研究使用了经过验证的问卷,其中包含 25 个多项选择题,涵盖了参与者的既往特征、接种疫苗后的副作用(其发作和持续时间)、接种疫苗后的医疗护理和危险因素。
共有 273 名运动员完成了调查。总体而言,(54.6%)的运动员报告至少有一种局部副作用,而(46.9%)报告至少有一种全身副作用。与灭活病毒和 mRNA 组相比,腺病毒载体组的这些副作用更为常见。最常见的局部副作用是注射部位疼痛(29.9%),而发烧(30.8%)是最常见的全身副作用。31-40 岁年龄组、过敏、以前感染过 COVID-19 和疫苗的第一剂与所有 COVID-19 疫苗组的副作用风险增加有关。逻辑回归分析进一步表明,与男性相比,女性报告的副作用发生率显著更高(优势比(OR)=1.16;P=0.015*),仅在腺病毒载体疫苗组中如此。此外,与高动态/低静态成分的运动员组相比,高动态/中静态或高动态/高静态成分的运动员组遭受疫苗接种后副作用的比例显著更高(OR=14.68 和 14.71;P<0.001,分别)。
腺病毒载体疫苗的副作用发生率最高,其次是灭活病毒和 mRNA COVID-19 疫苗。COVID-19 疫苗在阿尔及利亚运动员中耐受性良好,没有报告严重的副作用。然而,需要进一步对更大样本量的运动员(来自不同类型和运动类别)进行长期随访研究,以确定 COVID-19 疫苗的长期安全性。